Sugi Predict

Sugi Predict / Compounds / SCHEMBL5803074

SCHEMBL5803074

SCHEMBL5803074

COc1cc(-c2nn(C3CCC(N4CCN(C)CC4)CC3)c3ncnc(N)c23)ccc1NC(=O)c1cc2ccccc2n1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LCK P06239 19/20 1.00
▸ SRC P12931 15/20 1.00
▸ TEK Q02763 12/20 1.00
▸ FYN P06241 4/20 1.00
▸ LIMK1 P53667 3/20 0.89
▸ PLK4 O00444 2/20 0.89
▸ AURKA O14965 2/20 0.89
▸ PAK4 O96013 2/20 0.89
▸ CHEK2 O96017 2/20 0.89
▸ EGFR P00533 2/20 0.89
▸ ERBB2 P04626 2/20 0.89
▸ NTRK1 P04629 2/20 0.89
▸ INSR P06213 2/20 0.89
▸ CSF1R P07333 2/20 0.89
▸ LYN P07948 2/20 0.89
▸ FLT1 P17948 2/20 0.89
▸ NEK2 P51955 2/20 0.89
▸ PAK1 Q13153 2/20 0.89
▸ STK3 Q13188 2/20 0.89
▸ ROCK1 Q13464 2/20 0.89

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31061271 1.00 LCK (1.00) LCKSRCTEKFYNLIMK1
SCHEMBL6221049 1.00 LCK (1.00) LCKSRCTEKFYNLIMK1
SCHEMBL29457687 1.00 LCK (1.00) LCKSRCTEKFYNLIMK1
SCHEMBL16752208 1.00 LCK (1.00) LCKSRCTEKFYNLIMK1
SCHEMBL30521863 1.00 LCK (1.00) LCKSRCTEKFYNLIMK1
SCHEMBL19999345 1.00 LCK (1.00) LCKSRCTEKFYNLIMK1
SCHEMBL14106773 1.00 LCK (1.00) LCKSRCTEKFYNLIMK1
SCHEMBL6435493 0.94 LCK (0.89) LCKSRCTEKFYNLIMK1
SCHEMBL29562158 0.94 LCK (1.00) LCKSRCTEKFYNLIMK1
SCHEMBL29584810 0.94 LCK (1.00) LCKSRCTEKFYNLIMK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2878601-B1 AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA RIKEN (JP) 2018-03-28 — — EP claimed
US-20240041868-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2024-02-08 — — US disclosed
US-10688093-B2 Methods, compositions, and uses of novel Fyn kinase inhibitors Pathways Neuro Pharma, Inc. 2020-06-23 — — US disclosed
US-20190255056-A1 A HCK INHIBITOR AND A BCL-2 INHIBITOR FOR TREATING ACUTE MYELOID LEUKEMIA RIKEN (JP) 2019-08-22 — — US disclosed
EP-3512555-A1 A HCK INHIBITOR AND A BCL-2 INHIBITOR FOR TREATING ACUTE MYELOID LEUKEMIA Riken (JP) 2019-07-24 — — EP disclosed
US-20180250297-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2018-09-06 — — US disclosed
EP-2878601-B1 AGENT FOR TREATING OR CONTROLLING RECURRENCE OF ACUTE MYELOGENOUS LEUKEMIA RIKEN (JP) 2018-03-28 — — EP disclosed
WO-2018052120-A1 A HCK INHIBITOR AND A BCL-2 INHIBITOR FOR TREATING ACUTE MYELOID LEUKEMIA RIKEN (JP) 2018-03-22 — — WO disclosed
US-9604988-B2 Agent for treating or inhibiting recurrence of acute myeloid leukemia RIKEN (JP) 2017-03-28 — — US disclosed
US-20150210698-A1 AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA RIKEN (JP) 2015-07-30 — — US disclosed
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 — — US disclosed
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 — — US disclosed
WO-2004100868-A2 METHOD OF TREATING TRANSPLANT REJECTION ABBOTT LABORATORIES (US) 2004-11-25 — — WO disclosed
EP-1385524-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS Abbott GmbH & Co. KG (DE) 2004-02-04 — — EP disclosed
EP-1379528-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GmbH (DE) 2004-01-14 — — EP disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 — — US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 — — EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 — — US disclosed
WO-2002080926-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-17 — — WO disclosed
WO-2002076986-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN LCK 1/4885SRC 46/4885TEK 1465/4885
US-20240041868-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B LCK 2/4885SRC 9/4885TEK 1079/4885
US-20180250297-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B LCK 2/4885SRC 9/4885TEK 1079/4885
US-10688093-B2 Methods, compositions, and uses of novel Fyn kinase inhibitors FYN, LCK, PTK2B LCK 2/4885SRC 9/4885TEK 1079/4885
US-20190255056-A1 A HCK INHIBITOR AND A BCL-2 INHIBITOR FOR TREATING ACUTE MYELOID LEUKEMIA MCL1, HCK, FLT3 LCK 67/4885SRC 147/4885TEK 2044/4885
US-20150210698-A1 AGENT FOR TREATING OR INHIBITING RECURRENCE OF ACUTE MYELOID LEUKEMIA MCL1, BCOR, RUNX1 LCK 3635/4885SRC 395/4885TEK 2290/4885
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 LCK 1011/4885SRC 1834/4885TEK 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.